XML 21 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Stockholders' Equity
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
NOTE 4:–
STOCKHOLDERS’ EQUITY
 
a.
On December 30, 2005, the Company’s board of directors adopted the Varonis Systems, Inc. 2005 Stock Plan (the “2005 Stock Plan”). As of December 31, 2013, the Company had reserved 4,713,319 shares of common stock available for issuance to employees, directors, officers and consultants of the Company and its subsidiaries. The options generally vest over four years. No awards were granted under the 2005 Stock Plan subsequent to December 31, 2013, and no further awards will be granted under the 2005 Stock Plan.
 
On November 14, 2013, the Company’s board of directors adopted the Varonis Systems, Inc. 2013 Omnibus Equity Incentive Plan (the “2013 Plan”) which was subsequently approved by the Company’s stockholders. The Company initially reserved 1,904,633 shares of common stock available for issuance under the 2013 Plan to employees, directors, officers and consultants of the Company and its subsidiaries. The number of shares of common stock available for issuance under the 2013 Plan was increased on January 1, 2016 and will be increased on each January 1 thereafter by four percent (4%) of the number of shares of common stock issued and outstanding on each December 31 immediately prior to the date of increase (rounded down to the nearest whole share), but the amount of each increase will be limited to the number of shares of common stock necessary to bring the total number of shares of Common Stock available for grant and issuance under the 2013 Plan to five percent (5%) of the number of shares of common stock issued and outstanding on each December 31. As of March 31, 2016, the share reserve under the 2013 Plan was 2,947,399 shares of common stock. Awards granted under the 2013 Plan generally vest over four years. Any award that is forfeited or canceled before expiration becomes available for future grants under the 2013 Plan.
 
The fair value of stock option grants for the three months ended March 31, 2016 was estimated using the following weighted average assumptions:
 
    Three Months Ended
March 31, 2016
    (unaudited)
         
Expected dividend yield     0 %
Expected volatility     62 %
Risk-free interest rate     1.42 %
Expected term (years)     6.25  
 
A summary of employees’ stock options activities during the three months ended March 31, 2016 is as follows:
 
    Three Months Ended
March 31, 2016 (unaudited)
    Number   Average
exercise price
  Aggregate
intrinsic value
(in thousands)
  Average
remaining
contractual life
(years)
                 
Options outstanding as of January 1, 2016     2,782,560     $ 14.026     $ 21,337       6.246  
Granted     135,000     $ 16.870                  
Exercised     (15,181 )   $ 5.848                  
Forfeited     (23,391 )   $ 25.560                  
                                 
Options outstanding as of March 31, 2016     2,878,988     $ 14.119     $ 20,507       6.169  
                                 
Vested and expected to vest     2,783,465     $ 11.971     $ 20,471       6.095  
                                 
Options exercisable at the end of the period     1,911,497     $ 9.873     $ 19,736       5.019  
 
The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for the three months ended March 31, 2016 was $194.
 
b.
The options outstanding as of March 31, 2016 (unaudited) have been separated into ranges of exercise price as follows:
 
Range of exercise price   Options
outstanding
as of
March 31,
2016
  Weighted
average
remaining
contractual
life (years)
  Weighted
average
exercise price
  Options
exercisable
as of
March 31,
2016
  Weighted
average
remaining
contractual
life (years)
  Weighted
average
exercise price
of options
exercisable
                                 
$0.901   -   $1.576     974,178       2.682     $ 1.225       974,178       2.682     $ 1.225  
$6.230   -   8.800     136,650       5.670     $ 6.806       133,289       5.659     $ 6.807  
$12.470   -   16.870     510,698       7.710     $ 13.633       281,231       6.910     $ 12.470  
$19.510   -   21.660     622,311       8.363     $ 21.218       247,216       8.247     $ 21.243  
$22.010   -   24.230     308,524       8.050     $ 22.289       145,959       8.034     $ 22.349  
    $29.880         154,200       8.899     $ 29.880       41,772       8.899     $ 29.880  
    $39.860         172,427       7.978     $ 39.860       87,852       7.978     $ 39.860  
                                                         
              2,878,988       6.169     $ 14.119       1,911,497       5.019     $ 9.873  
 
 
c.
Options issued to consultants:
 
The Company’s outstanding options granted to consultants for sales and pre-marketing services as of March 31, 2016 (unaudited) were as follows:
 
   
Options for

shares of

common stock
 
Exercise price

per share
 
Options

exercisable
 
Exercisable

through
   
(number)
     
(number)
   
                             
February 2013
   
3,000
   
$
12.470
     
2,313
   
February 2023
August 2013
   
5,000
   
$
21.140
     
3,229
   
August 2023
October 2013
   
750
   
$
24.230
     
453
   
October 2023
March 2014
   
13,980
   
$
39.860
     
7,105
   
March 2024
May 2014
   
8,700
   
$
22.010
     
3,988
   
May 2024
November 2014
   
12,000
   
$
21.660
     
4,000
   
November 2024
May 2015
   
5,250
   
$
19.510
     
-
   
May 2025
February 2016
   
3,000
   
$
16.870
     
-
   
February 2026
                             
     
51,680
             
21,088
     
 
d. Restricted stock units:
 
A summary of restricted stock units for employees, consultants and non-employee directors of the Company for the three months ended March 31, 2016 is as follows:
 
    Number of
shares
underlying
outstanding
restricted stock
units
  Weighted-
average
grant date
fair value
Unvested balance - January 1, 2016     643,506     $ 23.38  
Granted     719,250     $ 16.87  
Vested     (72,785 )   $ 28.10  
Forfeited     (17,925 )   $ 18.91  
Unvested balance – March 31, 2016     1,272,046     $ 22.62  
 
As of March 31, 2016, there was $11,428 and $18,287 of total unrecognized compensation cost related to non-vested stock options and non-vested restricted stock units, respectively. This cost is expected to be recognized over a period of approximately 2.358 and 3.465 years for stock options and restricted stock units, respectively.
 
e.
2015 Employee Stock Purchase Plan
 
On May 5, 2015, the Company’s stockholders approved the Varonis Systems, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”), which the Company’s board of directors had adopted on March 19, 2015. The ESPP became effective as of June 30, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, at not less than 85% of the fair market value of the Company’s common stock on the first day or last trading day in the offering period, subject to any plan limitations. The Company initially reserved 500,000 shares of common stock for issuance under the ESPP. The number of shares available for issuance under the ESPP was increased on January 1, 2016, and will be increased on each January 1 thereafter, by an amount equal to the lesser of (i) one percent (1%) of the number of shares of common stock issued and outstanding on each December 31 immediately prior to the date of increase, except that the amount of each such increase will be limited to the number of shares of common stock necessary to bring the total number of shares of common stock available for issuance under the ESPP to two percent (2%) of the number of shares of common stock issued and outstanding on each such December 31, or (ii) 400,000 shares of common stock. As of March 31, 2016, the share reserve under the ESPP was 521,383 shares of common stock. The ESPP will continue in effect until the earlier of (i) the date when no shares of common stock are available for issuance thereunder or (ii) June 30, 2025; unless terminated prior thereto by the Company’s board of directors or compensation committee, each of which has the right to terminate the ESPP at any time.
 
f.
Stock-based compensation expense for employees and consultants:
 
The Company recognized non-cash stock-based compensation expense in the consolidated statements of operations as follows (in thousands):
 
   
Three Months Ended
March 31,
    2016   2015
    (unaudited)
    (in thousands)
         
Cost of revenues   $ 146     $ 91  
Research and development     665       467  
Sales and marketing     1,175       737  
General and administrative     638       390  
                 
Total   $ 2,624     $ 1,685